Kelly A. Teske
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelly A. Teske has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Leggy A. Arnold
Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, USA
10 shared publications Belaynesh Feleke
Department of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin, Milwaukee, Wisconsin 53211, United States
4 shared publicationsJames M. Cook
Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee , Milwaukee, Wisconsin 53201, United States
4 shared publications- Nina Y. Yuan
Stem Pharm, Incorporated, 2935 S Fish Hatchery Road PMB #235, Madison, WI 53711, USA
4 shared publications Preetpal S. Sidhu
Department of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin, Milwaukee, Wisconsin 53211, United States
4 shared publicationsPremchendar Nandhikonda
Department of Chemistry and Biochemistry, Milwaukee Institute for Drug Discovery, University of Wisconsin, Milwaukee, Wisconsin 53211, United States
4 shared publications
Latest Publications
- 1 February 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 188, 112008
A review of currently identified small molecule modulators of microRNA function
- 1 February 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 188, 112008
A review of currently identified small molecule modulators of microRNA function
- 21 June 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (14) , 6814-6823
Probing the Ligand-Binding Pocket of BTN3A1
Small-molecule phosphoantigens such as (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate stimulate human Vγ9Vδ2 T cells after binding to the intracellular B30.2 domain of the immune receptor butyrophilin 3 isoform A1 (BTN3A1). To understand the ligand–target interaction in greater detail, we performed molecular docking. Based on the docking results, we synthesized the novel ligand (E)-(7-hydroxy-6-methylhept-5-en-1-yl)phosphonate and mutated proposed binding site residues. We evaluated the impact on butyrophilin binding of existing and novel ligands using a newly developed high-throughput fluorescence polarization assay. We also evaluated the ability of the compounds to stimulate proliferation and interferon-γ production of Vγ9Vδ2 T cells. Mutation of H381 fully blocked ligand binding, whereas mutations to charged surface residues impacted diphosphate interactions. Monophosphonate analogs bind similarly to BTN3A1, although they differ in their antigenicity, demonstrating that binding and efficacy are not linearly correlated. These results further define the structure–activity relationships underlying BTN3A1 ligand binding and antigenicity and support further structure-guided drug design.
- 21 June 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (14) , 6814-6823
Probing the Ligand-Binding Pocket of BTN3A1
Small-molecule phosphoantigens such as (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate stimulate human Vγ9Vδ2 T cells after binding to the intracellular B30.2 domain of the immune receptor butyrophilin 3 isoform A1 (BTN3A1). To understand the ligand–target interaction in greater detail, we performed molecular docking. Based on the docking results, we synthesized the novel ligand (E)-(7-hydroxy-6-methylhept-5-en-1-yl)phosphonate and mutated proposed binding site residues. We evaluated the impact on butyrophilin binding of existing and novel ligands using a newly developed high-throughput fluorescence polarization assay. We also evaluated the ability of the compounds to stimulate proliferation and interferon-γ production of Vγ9Vδ2 T cells. Mutation of H381 fully blocked ligand binding, whereas mutations to charged surface residues impacted diphosphate interactions. Monophosphonate analogs bind similarly to BTN3A1, although they differ in their antigenicity, demonstrating that binding and efficacy are not linearly correlated. These results further define the structure–activity relationships underlying BTN3A1 ligand binding and antigenicity and support further structure-guided drug design.
- 21 March 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (8) , 3873-3885
Structure–Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors
The Food and Drug Administration-approved antifungal agent, itraconazole (ITZ), has been increasingly studied for its novel biological properties. In particular, ITZ inhibits the hedgehog (Hh) signaling pathway and has the potential to serve as an anticancer chemotherapeutic against several Hh-dependent malignancies. We have extended our studies on ITZ analogues as Hh pathway inhibitors through the design, synthesis, and evaluation of novel des-triazole ITZ analogues that incorporate modifications to the triazolone/side chain region of the scaffold. Our overall results suggest that the triazolone/side chain region can be replaced with various functionalities (hydrazine carboxamides and meta-substituted amides) resulting in improved potency when compared to ITZ. Our studies also indicate that the stereochemical orientation of the dioxolane ring is important for both potent Hh pathway inhibition and compound stability. Finally, our studies suggest that the ITZ scaffold can be successfully modified in terms of functionality and stereochemistry to further improve its anti-Hh potency and physicochemical properties.
- 21 March 2019
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (8) , 3873-3885
Structure–Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors
The Food and Drug Administration-approved antifungal agent, itraconazole (ITZ), has been increasingly studied for its novel biological properties. In particular, ITZ inhibits the hedgehog (Hh) signaling pathway and has the potential to serve as an anticancer chemotherapeutic against several Hh-dependent malignancies. We have extended our studies on ITZ analogues as Hh pathway inhibitors through the design, synthesis, and evaluation of novel des-triazole ITZ analogues that incorporate modifications to the triazolone/side chain region of the scaffold. Our overall results suggest that the triazolone/side chain region can be replaced with various functionalities (hydrazine carboxamides and meta-substituted amides) resulting in improved potency when compared to ITZ. Our studies also indicate that the stereochemical orientation of the dioxolane ring is important for both potent Hh pathway inhibition and compound stability. Finally, our studies suggest that the ITZ scaffold can be successfully modified in terms of functionality and stereochemistry to further improve its anti-Hh potency and physicochemical properties.
- 1 February 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 163, 320-332
Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors
- 1 February 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 163, 320-332
Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors
- 1 February 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (3) , 351-354
Novel VDR antagonists based on the GW0742 scaffold
- 1 February 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (3) , 351-354
Novel VDR antagonists based on the GW0742 scaffold
- 21 August 2017
- Published by American Chemical Society (ACS) in ACS Combinatorial Science
- Vol. 19 (10) , 646-656
Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold
We describe the parallel synthesis of novel analogs of GW0742, a peroxisome proliferator-activated receptor δ (PPARδ) agonist. For that purpose, modified reaction conditions were applied, such as a solid-phase palladium-catalyzed Suzuki coupling. In addition, tetrazole-based compounds were generated as a bioisostere for carboxylic acid-containing ligand GW0742. The new compounds were investigated for their ability to activate PPARδ mediated transcription and their cross-reactivity with the vitamin D receptor (VDR), another member of the nuclear receptor superfamily. We identified many potent PPARδ agonists that were less toxic than GW0742, where ∼65 of the compounds synthesized exhibited partial PPARδ activity (23–98%) with EC50 values ranging from 0.007–18.2 μM. Some ligands, such as compound 32, were more potent inhibitors of VDR-mediated transcription with significantly reduced PPARδ activity than GW0742, however, none of the ligands were completely selective for VDR inhibition over PPARδ activation of transcription.
- 21 August 2017
- Published by American Chemical Society (ACS) in ACS Combinatorial Science
- Vol. 19 (10) , 646-656
Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold
We describe the parallel synthesis of novel analogs of GW0742, a peroxisome proliferator-activated receptor δ (PPARδ) agonist. For that purpose, modified reaction conditions were applied, such as a solid-phase palladium-catalyzed Suzuki coupling. In addition, tetrazole-based compounds were generated as a bioisostere for carboxylic acid-containing ligand GW0742. The new compounds were investigated for their ability to activate PPARδ mediated transcription and their cross-reactivity with the vitamin D receptor (VDR), another member of the nuclear receptor superfamily. We identified many potent PPARδ agonists that were less toxic than GW0742, where ∼65 of the compounds synthesized exhibited partial PPARδ activity (23–98%) with EC50 values ranging from 0.007–18.2 μM. Some ligands, such as compound 32, were more potent inhibitors of VDR-mediated transcription with significantly reduced PPARδ activity than GW0742, however, none of the ligands were completely selective for VDR inhibition over PPARδ activation of transcription.
- 1 August 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 136, 14-35
Methyllysine binding domains: Structural insight and small molecule probe development
- 1 August 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 136, 14-35
Methyllysine binding domains: Structural insight and small molecule probe development
- 1 June 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 133, 197-207
Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells
- 1 June 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 133, 197-207
Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells
- 11 November 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (23) , 10800-10806
Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy
1,4-Benzodiazepines are used in the treatment of anxiety disorders but have limited long-term use due to adverse effects. HZ-166 (2) has been shown to have anxiolytic-like effects with reduced sedative/ataxic liabilities. A 1,3-oxazole KRM-II-81 (9) was discovered from a series of six bioisosteres with significantly improved pharmacokinetic and pharmacodynamic properties as compared to 2. Oxazole 9 was further characterized and exhibited improved anxiolytic-like effects in a mouse marble burying assay and a rat Vogel conflict test.
- 11 November 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (23) , 10800-10806
Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy
1,4-Benzodiazepines are used in the treatment of anxiety disorders but have limited long-term use due to adverse effects. HZ-166 (2) has been shown to have anxiolytic-like effects with reduced sedative/ataxic liabilities. A 1,3-oxazole KRM-II-81 (9) was discovered from a series of six bioisosteres with significantly improved pharmacokinetic and pharmacodynamic properties as compared to 2. Oxazole 9 was further characterized and exhibited improved anxiolytic-like effects in a mouse marble burying assay and a rat Vogel conflict test.
- 1 February 2016
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 109, 238-246
Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites
- 1 February 2016
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 109, 238-246
Synthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites